HFHuayi Feng

Huayi Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huayi Feng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • LGI3 promotes the progression of TFE3-rearranged renal cell carcinoma through GEMIN6/AURKB axis

    by Junxiao Liu, Huayi Feng, Zhuang Xiong, Shouqing Cao, Tianwei Cai, Wenjie Wei, Wen Tao, Xu Zhang, Xin Ma, Xiubin Li

    Transcription factor binding to IGHM enhancer 3-rearranged renal cell carcinoma (TFE3-RCC) is characterized by its aggressive nature, limited treatment options, and poor prognosis. However, the downstream targets of TFE3 fusion protein responsible for its tumorigenesis and progression remain unclear. Here, we demonstrated that leucine-rich repeat LGI family member 3 (LGI3) is a direct target of TFE3 fusion protein. TFE3 fusion protein can bind to the promoter of LGI3 and then activate its transcription. Importantly, LGI3 contributes to the proliferation, migration, and invasion of TFE3-RCC. Mechanistically, LGI3 interacts with gem nuclear organelle-associated protein 6 (GEMIN6) and inhibits its degradation via decreasing its ubiquitination. GEMIN6 upregulation promotes the mRNA maturation of Aurora B kinase (AURKB), thereby promoting the progression of TFE3-RCC. Importantly, drugs targeting GEMIN6 or AURKB significantly suppressed the growth of TFE3-RCC cells and organoids. In human TFE3-RCC tissues, LGI3 is highly expressed and positively correlated with GEMIN6 and AURKB. Overall, we revealed a novel mechanism underlying the progression of TFE3-RCC and provided potential new therapeutic targets.

  • Open Access

    Annexin A2 alleviates renal ischemia/reperfusion injury via regulating membranal ESCRT-III to suppress necroptosis of tubular epithelial cells

    by Xiubin Li, Dong Lai, Jichen Wang, Huayi Feng, Shouqing Cao, Huaikang Li, Qing Bi, Lili Bi, Wenmei Fan, Xu Zhang, et al.

    Renal functional impairment, resulting from nephron-sparing surgery (NSS), is mainly caused by ischemia-reperfusion injury (IRI) and majorly affects kidney function. Necroptosis plays an important role in renal IRI, however its mechanism remains unknown. We used Anxa2 knockout mice to investigate the role and mechanism of Anxa2 in renal IRI. Moreover, We further explored its underlying molecular mechanism by co-immunoprecipitation combined with mass spectrometry (IP-MS). Our results showed that Anxa2 accumulated significantly at the apical membrane of renal tubular epithelial cells of the medulla after renal IRI. In Anxa2 knockout mice, injury was significantly increased in the medulla rather than in the cortex, and necroptosis was found to be aggravated in medullary tubular epithelial cells accompanied by increased neutrophil infiltration in the injured area. Mechanistically, Anxa2 can specifically bind to Chmp2A after renal IR, an important component protein of endosomal sorting complex required for transport III (ESCRT-III). In knockout mice, membranal Chmp2A content in the renal medulla was significantly decreased, but not cytoplasmic Chmp2A. The other component proteins of the ESCRT-III complex, such as Chmp2B, Chmp3, Chmp4B and Vps4B, followed the same trend as Chmp2A. We also found that Cxcl1and Cxcl2, which are specific neutrophil chemokines, were significantly upregulated without Anxa2 expression both in vivo and in vitro. Moreover, Necrostatin 1 (Nec1), a specific necroptosis inhibitor, rescued the Anxa2 deficiency-induced necroptosis, neutrophil infiltration and IRI. This study demonstrates that Anxa2 can inhibit necroptosis of renal medullary tubular epithelial cells, reduce local neutrophil infiltration and inflammatory factors, and protect against the renal IRI. More importantly, we describe the molecular mechanism by which Anxa2 inhibits necroptosis by regulating ESCRT-III. Our study clarified the role and mechanism of Anxa2 function in renal IRI, providing new clinical strategies for its prevention and treatment.

  • Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma

    by Jiali Ye, Xing Huang, Shuo Tian, Jichen Wang, Hanfeng Wang, Huayi Feng, Xupeng Zhao, Shouqing Cao, Yundong Xuan, Xiubin Li, et al.


  • Open Access

    SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma

    by Huayi Feng, Tao Wang, Jiali Ye, Yang Yang, Xing Huang, Dong Lai, Zheng Lv, Yan Huang, Xu Zhang

    Background: Spi-1 proto-oncogene (SPI1), which encodes an ETS-domain transcription factor, can activate gene expression in myeloid and lymphoid lineages. The role of SPI1 in the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC) remains unknown. In this study, we investigated the possible role of SPI1 in ccRCC using an independent cohort and a comprehensive bioinformatics analysis. Materials and methods: Quantitative real-time PCR, western blot and immunohistochemistry assays were used to compare the SPI1 expression levels between ccRCC tissues and normal tissues, analyze the relationships between SPI1 and CD68, CD8, CD4 expression levels, and explore the link between SPI1 and the efficacy of immunotherapy in our cohort. Tumor Immune Estimation Resource, UALCAN, cBioPortal, TISIDB database, and LinkedOmics database were used in our study. Results: SPI1 expression level was higher in ccRCC bulk tissues than in normal bulk tissues. SPI1 was an independent prognostic factor for poor overall survival and progression-free survival in patients with ccRCC. SPI1 expression was strongly related to the infiltration of immune cells and immune-related molecules. SPI1 was more highly expressed in tumor-infiltrating immune cells rather than in cancer cells. Non-responders to immunotherapy against ccRCC were more likely to express higher SPI1 levels than responders. Genes co-expressed with SPI1 primarily correlated with immune-related pathways. Conclusions: SPI1 expression in tumor bulk tissues is associated with disease progression and poor prognosis, as well as high expression levels of immune markers and infiltration of immune cells. SPI1 can be used as a prognostic biomarker to monitor and evaluate immunotherapy efficacy.


  • Open Access

    CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates

    by Zheng Lv, Hua-Yi Feng, Wang Tao, Hong-Zhao Li, Xu Zhang

    Backgrounds: CD146 is highly expressed in various malignant tumors and associated with the poor prognosis. However, the role of CD146 in clear cell renal cell carcinoma (ccRCC) is still unknown. This study aimed to identify the role of CD146 in ccRCC by integrated bioinformatics analysis. Methods: CD146 mRNA expression and methylation data in ccRCC was examined using the TIMER, UALCAN, and MethSurv databases. CD146 expression in paraffin-embedded tissues (140 cancer samples and 140 paracancer tissues) from our cohort were examined by immunohistochemistry assay. The LinkedOmics database was used to study the signaling pathways related to CD146 expression. TIMER and TISIDB were used to analyze the correlations among CD146, CD146-coexpressed genes, tumor-infiltrating immune cells, and immunomodulators. The relationship between CD146 and drug response in renal cancer cell lines was analyzed by the CTRP and CCLE databases. Results: The mRNA and protein levels of CD146 were elevated in ccRCC tissues than that in paracancer tissues. The DNA methylation of CD146 in ccRCC tissues were lower than that in normal tissues. Importantly, high CD146 expression was associated with poor prognosis in patients with ccRCC. Furthermore, multivariate Cox regression analysis showed that CD146 was an independent prognostic factor in ccRCC. GO and KEGG pathway analyses indicated the co-expressed genes of CD146 were mainly related to a variety of immune-related pathways, including Th1 and Th2 cell differentiation, Th17 cell differentiation, and leukocyte transendothelial migration. Our data demonstrated that the expression and methylation status of CD146 were strongly correlated with immune infiltration levels, immunomodulators, and chemokines. Further, the sensitivity and resistance of renal cancer cell lines to some drugs were related to CD146 expression. Conclusions: Our study highlights the clinical significance of CD146 in ccRCC and provides novel insights into the immune function of CD146 in the tumor microenvironment.